Interleukin-6 blocker for successful outcome of late-onset rheumatoid oligoarthritis

Newer cytokine therapies have revolutionised the management of Rheumatoid arthritis. Atypical oligoarthritis can also be a manifestation of RA and CCP antibodies have been proven to be most specific for Rheumatoid. Our patient had 2 years of painful ankle bilaterally and suggested for joint replacement due to osteoarthritis changes. After the diagnosis of RA using Anti-CCP antibodies, we elected to give Tocilizumab(IL 6 Blocker) which had made the patient to walk without wheelchair after 2 years. This suggests early appropriate diagnosis is the key and Biologics- the new Kid in the market- has proven to be effective in early Rheumatoid arthritis.